This Pot Stock Could Go From $400 Million to $4 Billion

Hexo Corp (TSX:HEXO)(NYSE:HEXO) is closing major pot deals with heavyweights like Molson Coors Canada Inc. (TSX:TPX.B)(NYSE:TAP).

| More on:
edit Jars of marijuana

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Hexo Corp (TSX:HEXO)(NYSE:HEXO) isn’t a big pot stock. It’s worth only $400 million. Many of its competitors are worth several billion dollars. But if you’re looking for big upside, this is the stock for you.

It all comes down to strategy. From the start, Hexo took a unique route. The rest of the industry followed a traditional path. This is why such a large opportunity exists. Hexo bucks the trend.

Over the next several years, Hexo stock could rise 10 times in value. Before we crunch the numbers, let’s take a look at how you can take advantage.

A rare opportunity

The marijuana business is booming. Cowen recently increased its U.S. sales forecast to US$80 billion. That’s the third consecutive increase. The firm thinks that the Canadian market will eventually top US$5 billion.

The most intriguing growth opportunity is with Cannabis 2.0. This phase kicked off when Canada legalized value-add products like edibles, vapes, beverages, and concentrates. “Many analysts are optimistic that Cannabis 2.0 could add more revenue to the sector by 2020,” reports Market Realist.

Despite the COVID-19 crisis, we’re still seeing a boom in recreational and medical pot demand in North America. This trend won’t be interrupted through at least 2030.

Why, then, aren’t pot stocks benefiting? Year to date, Hexo shares have lost 50% of their value. As we’ll see, this is a powerful mismatch that should heavily reward patient investors.

This pot stock is ready

Cannabis 1.0 focused on the raw cultivation of pot. While this initial boom was exciting, it ultimately proved unprofitable. The real profits will stem from less commoditized products introduced through the Cannabis 2.0 phase. Hexo was built for this environment.

In 2019, when the competition was focused on growing production as quickly as possible, Hexo opted to secure long-term partnerships with well-known brands. It was a risky strategy at the time, but it’s clear now that those moves will pay dividends for years to come.

One of its partnerships is with Molson Coors Canada Inc. The companies agreed last year to co-produce and co-brand a pot-infused beverage for Canadian markets. Last month, the partnership was expanded to include the U.S. market.

This deal alone could add $100 million in sales next year, meaning Hexo trades at just four times forward sales. But this co-branding strategy should pay off much bigger than that.

By the end of 2020, Hexo hopes to secure additional partnership with worldwide brands in cosmetics, sleep aids, consumables, and more. As these pot products hit the mainstream, Hexo won’t need to gain consumer trust. Instead, it can leverage brands that buyers already know and love.

The future of marijuana isn’t smokable. The biggest sales will be derived from value-add products. Hexo is years ahead of the competition. It plans to launch additional Cannabis 2.0 products by the end of this year.

With a $400 million valuation, Hexo is no longer priced as a growth stock. This will take more than a few months to play out, but if you’re willing to remain patient, there’s no better pot company to bet on.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends HEXO. and HEXO. Fool contributor Ryan Vanzo has no position in any stocks mentioned.

More on Coronavirus

little girl in pilot costume playing and dreaming of flying over the sky
Coronavirus

Air Canada Stock: How High Could it go?

AC stock is up 29% in the last six months alone, so should we expect more great things? Or is…

Read more »

eat food
Coronavirus

Goodfood Stock Doubles Within Days: Time to Buy?

Goodfood (TSX:FOOD) stock has surged 125% in the last few weeks, so what happened, and should investors hop back on…

Read more »

stock data
Tech Stocks

If I Could Only Buy 1 Stock Before 2023, This Would Be It

This stock is the one company that really doesn't deserve its ultra-low share price, so I'll definitely pick it up…

Read more »

Aircraft Mechanic checking jet engine of the airplane
Coronavirus

Air Canada Stock Fell 5% in November: Is it a Buy Today?

Air Canada (TSX:AC) stock saw remarkable improvements during its last quarter but still dropped 5% with more recession hints. So,…

Read more »

Airport and plane
Coronavirus

Is Air Canada Stock a Buy Today?

Airlines are on the rebound. Does Air Canada stock deserve to be on your buy list?

Read more »

A patient takes medicine out of a daily pill box.
Coronavirus

Retirees: 2 Healthcare Stocks That Could Help Set You up for Life

Healthcare stocks offer an incredible opportunity for growth for those investors who look to the right stocks, such as these…

Read more »

sad concerned deep in thought
Coronavirus

Here’s Why I Just Bought WELL Health Stock

WELL Health stock (TSX:WELL) may be a healthcare stock and a tech stock, but don't let that keep you from…

Read more »

healthcare pharma
Coronavirus

WELL Stock: The Safe Stock Investors Can’t Afford to Ignore

WELL stock (TSX:WELL) fell 68% from peak to trough, and yet there's no good reason as to why. So now…

Read more »